SRTD Biotech (srtd-biotech.com): no confident changes recorded yet; website history since November 2026. Homepage last checked 11 November 2026.
First recorded website
Observed 11 November 2026
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
seRNA – The Next Generation of RNA Therapeutics
SRTD Biotech develops selectively expressed RNA (seRNA) therapies that activate only in diseased cells, for oncology, autoimmune and fibrosis indications.
Homepage
Funding statements on the website
pipeline Latest News November 09, 2026 SRTD Biotech raises a €31.5 million seed round to develop next-generation precision mRNA therapeutics.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
Recorded changes
Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
No changes recorded yet. Missing observations do not mean the company has not changed.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
Seen November 2026 · 1 capture · latest observed messagingseRNA – The Next Generation of RNA Therapeutics
SRTD Biotech develops selectively expressed RNA (seRNA) therapies that activate only in diseased cells, for oncology, autoimmune and fibrosis indications.